Psychiatric issues in older cancer patients

Critical Reviews in Oncology/Hematology

Volumn 48, Issue 2, 2003, Pages 185-197

  Roth, Andrew J ^a   Modi, Reena ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Anxiety; Delirium; Depression; Elderly; Psychiatric

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CHLORPROMAZINE; CITALOPRAM; DESIPRAMINE; DEXAMPHETAMINE; FLUOXETINE; HALOPERIDOL; METHYLPHENIDATE; MIRTAZAPINE; MODAFINIL; NEFAZODONE; NEUROLEPTIC AGENT; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PEMOLINE; PSYCHOSTIMULANT AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; UNINDEXED DRUG; VENLAFAXINE; ZIPRASIDONE;

AGGRESSIVENESS; AGITATION; AKATHISIA; ANOREXIA; ANORGASMIA; ANTICHOLINERGIC EFFECT; ANXIETY DISORDER; ASTHENIA; AWARENESS; CANCER; CEREBROVASCULAR ACCIDENT; CONFERENCE PAPER; CONFUSION; CONSTIPATION; COPING BEHAVIOR; DELIRIUM; DEPRESSION; DIAGNOSTIC TEST; DISORIENTATION; DISTRESS SYNDROME; DROWSINESS; DYSTONIA; EDUCATION; EXTRAPYRAMIDAL SYMPTOM; FATALITY; GASTROINTESTINAL SYMPTOM; GERIATRICS; GLUCOSE INTOLERANCE; GROUP THERAPY; HALLUCINATION; HEADACHE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; HYPERACTIVITY; HYPERTENSION; HYPERTENSIVE CRISIS; HYPOTENSION; INSOMNIA; INTESTINE MOTILITY; IRRITABILITY; LETHARGY; LIVER TOXICITY; MEMORY DISORDER; MYOCLONUS; NARCOLEPSY; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; NEUROTOXICITY; NEUTROPENIA; NIGHTMARE; ORTHOSTATIC HYPOTENSION; PSYCHOSIS; PSYCHOTHERAPY; QT INTERVAL; RESPIRATION DEPRESSION; RESTLESSNESS; RISK FACTOR; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SOMNOLENCE; STANDING; STRESS; STROKE; SUPPORT GROUP; SURVIVAL RATE; SYMPTOMATOLOGY; TACHYCARDIA; TARDIVE DYSKINESIA; TORSADE DES POINTES; TREATMENT OUTCOME; TREMOR; URINE RETENTION; VERTIGO; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 0242320964     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2003.06.004     Document Type: Conference Paper

References (66)

1. Holland J.C., Rowland J., Lebovits A.et al. Reactions to cancer treatment: assessment of emotional response to adjunct radiotherapy. Psychiatr. Clin. North Am. 2:1979;347-358.
2. Holland JC. Psychological aspects of cancer. In: Holland JF, Frei E, editors. Cancer medicine. 2nd ed. Philadelphia: Lea & Febiger; 1982. p. 1175-203.
3. Wells K.B., Rogers W., Burnham M.A.et al. Course of depression in patients with hypertension, myocardial infarction, or insulin-dependent diabetes. Am. J. Psychiatry. 150:1993;632-638.
4. Passik S.D., Donaghy K.B., Theobald D.E., Lundberg J.C., Holtsclaw E., Dugan W.M. Oncology staff recognition of depressive symptoms on videotaped interviews of depressed cancer patients: implications for designing a training program. J. Pain Symptom Manage. 19:2000;329-338.
5. Blazer DG. Epidemiology of late life depression. In: Schneider LS, Reynolds CF, Lebowitz BD, Friedhoff AJ, editors. Diagnosis and treatment of depression in late life. Washington, DC: American Psychiatric Press; 1994. p. 9-19.
6. Kurtz M.E., Kurtz J.C., Stommel M.et al. Physical functioning and depression among older persons with cancer. Cancer Pract. 9:2001;11-18.
7. Dewey M., de la Camara C., Copeland J.R.M.et al. Cross-cultural comparison of depression and depressive symptoms in older people. Acta Psychiatr. Scand. 87:1993;369-373.
8. National Comprehensive Cancer Network. NCCN practice guidelines for the management of psychosocial distress. Oncology 1999;13:113-47.
9. Roth A.J., Kornblith A.B., Batel-Copel L.et al. Rapid screening for psychologic distress in men with prostate cancer: a pilot study. Cancer. 82:1998;1904-1908.
10. Yesavage J., Brink T.L. Development and validation of a geriatric depression screening scale: a preliminary report. J. Psychiatry Res. 17:1983;37-49.
11. Zigmond A.S., Snaith R.P. The Hospital Anxiety and Depression Scale. Acta Psychiatr. Scand. 67:1983;361-370.
12. Radloff L.S. The CES-D: a self-report depression scale for research in the general population. Appl. Psychol. Meas. 3:1977;385-401.
13. Lyness J.M., Noel T.K., Cox C., King D.A., Conwell Y., Caine E.D. Screening for depression in elderly primary care patients. A comparison of the Center for Epidemiologic Studies-Depression Scale and the Geriatric Depression Scale. Arch. Intern. Med. 157(4):1997;449-454.
14. Bukberg J., Penman D., Holland J.C. Depression in hospitalized cancer patients. Psychosom. Med. 46:1984;199-212.
15. Moffic H.S., Paykel E.S. Depression in medical in-patients. Br. J. Psychiatry. 126:1975;346-353.
16. Schwab J.J., Bialow M., Brown J.M., Holzer C.E. Diagnosing depression in medical inpatients. Ann. Intern. Med. 67:1967;695-707.
17. Holland J.C., Morrow G.R., Schmale A.et al. A randomized clinical trial of alprazolam versus progressive muscle relaxation in cancer patients with anxiety and depressive symptoms. J. Clin. Oncol. 9:1991;1004-1011.
18. Massie M.J., Holland J.C. Depression and the cancer patient. J. Clin. Psychiatry. 51(Suppl):1990;12-17.
19. Green A.I., Austin C.P. Psychopathology of pancreatic cancer. A psychobiologic probe. Psychosomatics. 34:1993;208-221.
20. Kissane D.W., Clark D.M., Street A.F. Demoralization syndrome - a relevant psychiatric diagnosis for palliative care. J. Palliat. Care. 17:2001;12-21.
21. Spiegel D., Bloom J.R., Kraemer H.J.C.et al. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet. 14:1989;888-891.
22. Fawzy F.I., Fawzy W.W., Hyun C.S.et al. Malignant melanoma. Effects of an early structured psychiatric intervention, coping and affective state on recurrence and survival 6 years later. Arch. Gen. Psychiatry. 50:1993;681-689.
23. Brandes L.J., Arron R.J., Bogdanovic R.P. Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses. Cancer Res. 52(13):1992;3796-3800.
24. Miller F.G. Antidepressants and cancer: cause for concern? J. Clin. Psychopharmacol. 13:1993;1-2.
25. Matthews J. Concern over Prozac-induced tumor growth may dwindle following FDA study. JNCI. 87:1995;1285-1287.
26. Keller M.B. Long-term treatment strategies in affective disorders. Psychopharmacol. Bull. 36(Suppl 2):2002;36-48.
27. Schatzberg A.F. Pharmacological principles of antidepressant efficacy. Hum. Psychopharmacol. 17(Suppl 1):2002;S17-S22.
28. Beers M.H. Explicit criteria for determining potentially inappropriate medication use by the elderly. Arch. Intern. Med. 157:1997;1531-1536.
29. Golden A.G., Preston R.A., Barnett S.D.et al. Inappropriate medication prescribing in homebound older adults. J. Am. Geriatr. Soc. 47:1999;948-953.
30. Aparasu R.R., Mort J.R. Inappropriate prescribing for the elderly: Beers criteria-based review. Ann. Pharmacother. 34:2000;338-346.
31. Meredith S., Feldman P.H., Frey D., Hall K.et al. Possible medication errors in home healthcare patients. J. Am. Geriatr. Soc. 49:2001;719-724.
32. Dhall I.A., Anderson G.M., Mamdani M.M., Bronskill S.E.et al. Inappropriate prescribing before and after nursing home admission. J. Am. Geriatr. Soc. 50:2002;995-1000.
33. Liu G.G., Christensen D.B. The continuing challenge of inappropriate prescribing in the elderly: an update of the evidence. J. Am. Pharm. Assoc. 42:2002;847-857.
34. Olin J., Masand P. Psychostimulants for depression in hospitalized cancer patients. Psychosomatics. 37:1996;57-62.
35. Masand P.S., Tesar G.E. Use of stimulants in the medically ill. Psychiatr. Clin. North Am. 19:1996;515-547.
36. Burns M.M., Eisendrath S.J. Dextroamphetamine treatment for depression in terminally ill patients. Psychosomatics. 35:1994;80-83.
37. Fernandez F., Adams F., Levy J.et al. Cognitive impairment due to AIDS related complex and its response to psychostimulants. Psychosomatics. 29:1988;38-46.
38. Bruera E., Chadwick S., Brennels C.et al. Methylphenidate associated with narcotics for the management of depressive disorders in cancer patients. Psychosomatics. 33:1992;352-356.
39. Bruera E., MacMillan K., Hanson J.et al. The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain. 39:1989;13-16.
40. Robinson D.S. Monoamine oxidase inhibitors: a new generation. Psychopharmacol. Bull. 36(3):2002;124-138.
41. Schwartz L., Lander M., Chochinov H.M., Current M. Management of depression in cancer patients. Oncology (Huntington). 16(8):2002;1102-1110. Discussion 1110, 1114-5.
42. Kalso E., Tasmuth T., Neuvonen P.J. Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. Pain. 64:1996;293-302.
43. Kast R.E. Mirtazapine may be helpful in treating nausea and insomnia of cancer chemotherapy. Support Care Cancer. 9:2001;469-470.
44. Musselman D.L., Lawson D.H., Gumnick J.F. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N. Engl. J. Med. 344:2001;961-966.
45. Roth A.J., Scher H.I. Sertraline relieves hot flashes secondary to medical castration as treatment of advanced prostate cancer. Psychooncology. 7:1998;129-132.
46. Loprinzi C.L., Sloan J.A., Perez E.A.et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J. Clin. Oncol. 20:2002;1578-1583.
47. Weitzner M.A., Moncello J., Jacobsen P.B., Minton S. A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer. J. Pain Symptom Manage. 23:2002;337-345.
48. Loprinzi C.L., Kugler J.W., Sloan J.A.et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet. 356:2000;2059-2063.
49. Passik S.D., Roth A.J. Anxiety symptoms and panic attacks preceding pancreatic cancer diagnosis. Psychooncology. 8:1999;268-272.
50. Massie M.J., Holland J.C., Glass E. Delirium in terminally ill cancer patients. Am. J. Psychiatry. 140:1983;1048-1050.
51. Breitbart W. Diagnosis and management of delirium in the terminally ill. In: Topics in palliative care, Vol. 5. Oxford: Oxford University Press; 2001. p. 303-21.
52. Hammerlid E., Ahlner-Elmqvist M., Bjordal K.et al. A prospective multicentre study in Sweden and Norway of mental distress and psychiatric morbidity in head and neck cancer patients. Br. J. Cancer. 80:1999;766-774.
53. Stiefel F.C., Breitbart W.S., Holland J.C. Corticosteroids in cancer: neuropsychiatric complications. Cancer Invest. 7:1989;479-491.
54. Denicoff K.D., Rubinow D.R., Papa M.Z.et al. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann. Intern. Med. 107:1987;293-300.
55. Patten S.B., Love E.J. Drug-induced depression. Psychother. Psychosom. 66:1997;63-73.
56. Lerner D.M., Stoudemire A., Rosenstein D.L. Neuropsychiatric toxicity associated with cytokine therapies. Psychosomatics. 40:1999;428-435.
57. Walker L.G., Walker M.B., Heys S.D.et al. The psychological and psychiatric effects of rIL-2 therapy: a controlled clinical trial. Psychooncology. 6:1997;290-301.
58. Breitbart W., Wein S.E. Metabolic disorders and neuropsychiatric symptoms. Psychooncology. 56:1998;639.
59. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975;189-98.
60. Stiefel F., Razavi D. Common psychiatric disorders in cancer patients. II. Anxiety and acute confusional states. Support Care Cancer. 2:1994;223-237.
61. Murray GB. Confusion, delirium and dementia. In: Hackett TP, Cassem NH, editors. Massachusetts General Hospital handbook of general hospital psychiatry. 2nd ed. Littleton, MA: PSG Publishing; 1987. p. 84.
62. Stiefel F., Holland J. Delirium in cancer patients. Int. Psychogeriatr. 3:1991;333-336.
63. Akechi T., Uchitomi Y., Okamura H.et al. Usage of haloperidol for delirium in cancer patients. Support Care Cancer. 4:1996;390-392.
64. Breitbart W., Marotta R., Platt M.M.et al. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am. J. Psychiatry. 153:1996;231-237.
65. Sipahimalani A., Masand P.S. Olanzapine in the treatment of delirium. Psychosomatics. 39:1998;422-430.
66. Breitbart W., Tremblay A., Gibson C. An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients. Psychosomatics. 43:2002;175-182.